Polypharmacology of Approved Anticancer Drugs
Polypharmacology of Approved Anticancer Drugs
No Thumbnail Available
Files
There are no files associated with this item.
Date
2017
Authors
Editors
Journal ISSN
Electronic ISSN
ISBN
Bibliographical data
Publisher
Series
DOI (citable link)
International patent number
Link to the license
EU project number
Project
Open Access publication
Collections
Title in another language
Publication type
Journal article
Publication status
Published
Published in
Current Drug Targets ; 18 (2017), 5. - pp. 534-543. - Bentham Science. - ISSN 1389-4501. - eISSN 1873-5592
Abstract
The major drug discovery efforts in oncology have been concentrated on the development of selective molecules that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets. However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions. Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action. Polypharmacology of the current antineoplastic agents suggests that drug clinical efficacy in oncology can be achieved only via modulation of multiple cellular mechanisms.
Summary in another language
Subject (DDC)
570 Biosciences, Biology
Keywords
Polypharmacology, tyrosine kinase inhibitors, histone deacetylase inhibitors, DNA topoisomerase inhibitors, tamoxifen, drug targets, rational design of multitarget drugs
Conference
Review
undefined / . - undefined, undefined. - (undefined; undefined)
Cite This
ISO 690
AMELIO, Ivano, Andrey LISITSA, Richard A. KNIGHT, Gerry MELINO, Alexey V. ANTONOV, 2017. Polypharmacology of Approved Anticancer Drugs. In: Current Drug Targets. Bentham Science. 18(5), pp. 534-543. ISSN 1389-4501. eISSN 1873-5592. Available under: doi: 10.2174/1389450117666160301095233BibTex
@article{Amelio2017Polyp-56667, year={2017}, doi={10.2174/1389450117666160301095233}, title={Polypharmacology of Approved Anticancer Drugs}, number={5}, volume={18}, issn={1389-4501}, journal={Current Drug Targets}, pages={534--543}, author={Amelio, Ivano and Lisitsa, Andrey and Knight, Richard A. and Melino, Gerry and Antonov, Alexey V.} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/56667"> <dc:creator>Amelio, Ivano</dc:creator> <dc:creator>Melino, Gerry</dc:creator> <dcterms:title>Polypharmacology of Approved Anticancer Drugs</dcterms:title> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dc:language>eng</dc:language> <dcterms:abstract xml:lang="eng">The major drug discovery efforts in oncology have been concentrated on the development of selective molecules that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets. However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions. Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action. Polypharmacology of the current antineoplastic agents suggests that drug clinical efficacy in oncology can be achieved only via modulation of multiple cellular mechanisms.</dcterms:abstract> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dcterms:issued>2017</dcterms:issued> <foaf:homepage rdf:resource="http://localhost:8080/"/> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-02-23T14:42:45Z</dc:date> <dc:contributor>Knight, Richard A.</dc:contributor> <dc:contributor>Amelio, Ivano</dc:contributor> <dc:contributor>Lisitsa, Andrey</dc:contributor> <dc:contributor>Antonov, Alexey V.</dc:contributor> <dc:creator>Knight, Richard A.</dc:creator> <dc:creator>Antonov, Alexey V.</dc:creator> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/56667"/> <dc:creator>Lisitsa, Andrey</dc:creator> <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/> <dc:contributor>Melino, Gerry</dc:contributor> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-02-23T14:42:45Z</dcterms:available> <dc:rights>terms-of-use</dc:rights> </rdf:Description> </rdf:RDF>
Internal note
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Examination date of dissertation
Method of financing
Comment on publication
Alliance license
Corresponding Authors der Uni Konstanz vorhanden
International Co-Authors
Bibliography of Konstanz
No
Refereed
Yes